Table 1.

Baseline patient characteristics.

Characteristic	All patients (n = 70)
Median age, years	51 (23–70)
Age group, years
≤40	22 (31.4)
>40	48 (68.6)
Menopausal status
Premenopausal	28 (40.0)
Postmenopausal	42 (60.0)
ECOG performance status
0	60 (85.7)
1	10 (14.3)
Tumor stage
T2	43 (61.4)
T3–4	27 (38.6)
Clinical nodal status
Negative	5 (7.1)
Positive	65 (92.9)
Clinical stage
Stage II
Stage IIA	4 (5.7)
Stage IIB	22 (31.4)
Stage III
Stage IIIA	29 (41.4)
Stage IIIB	4 (5.7)
Stage IIIC	11 (15.7)
Tumor grade
G2	11 (15.7)
G3	59 (84.3)
Ki-67 expression
≤50%	28 (40.0)
>50%	42 (60.0)
CD8 expression
<10%	20 (28.6)
≥10%	50 (71.4)
HER2 status score
0	23 (32.9)
1+	29 (41.4)
2+	18 (25.7)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; CD8, cluster of differentiation 8; HER2, human epidermal growth factor receptor 2.